02171

9.3004.71%
ZL

Zonghai Li

Co-Founder, CEO, Chief Scientific Officer & Chairman of the Board

Dr. Zonghai Li M.D., Ph.D., is Co-Founder of CARsgen Therapeutics Holdings Limited and serves as its Chief Executive Officer and Chief Scientific Officer since February 2021 and serves as its Chairman of the Board. and serves as its Director since February 2018. He serves as Chief Executive Officer, Founder and Chief scientific Officer at CARsgen Therapeutics, Ltd. and served as its President. He was re-designated as an Executive Director in February 2021. Dr. Li has also held positions at CARsgen Therapeutics. He has been a Director and the Chief Executive Officer since October 2014 and the Chief scientific officer since December 2017. Dr. Li has years of work experience in the biopharmaceutical field. Dr. Li was a project Manager at Guilin Pavay Gene Pharmaceutical Co., Ltd. from July 2000 to April 2002. Dr. Li worked at Shanghai Cancer Institute from July 2005 to June 2018 and served as the leader of the biotherapy research team at the State Key Laboratory of Oncogenes and Related Genes of Shanghai Cancer Institute during such period. Dr. Li has dedicated himself to developing innovative treatment for the patients with cancer. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. Dr. Li obtained his bachelor’s degree in preventive medicine and master’s degree in pathology and pathogen biology from the Central South University formerly known as the Hunan Medical University the PRC, in June 1997 and July 2000 respectively. He obtained his Doctor of Philosophy degree in pathogen biology from Fudan University, the PRC, in June 2005.

Positions